GALD Stock Analysis: Galderma N | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 38.196m CHF | 12M Return: 20.7% | CH1335392721 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 95.4M
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galderma Group AG is a Switzerland-based dermatology company founded in 1981 and headquartered in Zug, operating worldwide across three main segments: injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio spans a broad range of well-known brands, including injectables and aesthetics products such as Dysport, Restylane, Sculptra, and Azzalure, consumer skincare lines like Cetaphil and ALASTIN, and prescription therapeutics including Soolantra, Epiduo, Differin, Oracea, and NEMLUVIO.
The company operates a hybrid business model that combines consumer skincare products, medical aesthetic treatments, and prescription dermatology therapies, allowing it to serve patients, practitioners, and consumers across both over-the-counter and regulated pharmaceutical channels.
- NEMLUVIO launch accelerates atopic dermatitis revenue growth
- Injectable aesthetics margins pressured by Evolus and Revance competition
- GLP-1 weight loss drugs drive demand for skin laxity and aesthetic treatments
| Net Income: 857.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.86 > 1.0 |
| NWC/Revenue: 8.85% < 20% (prev 3.36%; Δ 5.49% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.16b > Net Income 857.0m |
| Net Debt (2.01b) to EBITDA (1.33b): 1.51 < 3 |
| Current Ratio: 1.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (189.7m) vs 12m ago -20.15% < -2% |
| Gross Margin: 66.95% > 18% (prev 68.99%; Δ -2.04% > 0.5%) |
| Asset Turnover: 44.24% > 50% (prev 36.97%; Δ 7.27% > 0%) |
| Interest Coverage Ratio: 7.77 > 6 (EBIT TTM 998.7m / Interest Expense TTM 128.5m) |
| A: 0.04 (Total Current Assets 2.66b - Total Current Liabilities 2.14b) / Total Assets 13.6b |
| B: 0.50 (Retained Earnings 6.82b / Total Assets 13.6b) |
| C: 0.08 (EBIT TTM 998.7m / Avg Total Assets 13.2b) |
| D: 1.55 (Book Value of Equity 8.24b / Total Liabilities 5.33b) |
| Altman-Z'' = 4.02 = AA |
| DSRI: 0.95 (Receivables 1.09b/931.0m, Revenue 5.85b/4.76b) |
| GMI: 1.03 (GM 68.99% / 66.95%) |
| AQI: 0.93 (AQ_t 0.75 / AQ_t-1 0.80) |
| SGI: 1.23 (Revenue 5.85b / 4.76b) |
| TATA: -0.02 (NI 857.0m - CFO 1.16b) / TA 13.6b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at CHF 163.00 with a total of 527,779 shares traded. Over the past week, the price has changed by +3.07%, over one month by -5.01%, over three months by -8.68% and over the past year by +20.74%.
Current recommended Stop Loss: 155.00 (which is 4.9% or 1.7 ATR below the current price).
Galderma N has no consensus analysts rating.
Market Cap USD = 46.1b (38.2b CHF * 1.2066 CHF.USD)
P/E Trailing = 54.6
P/E Forward = 30.3951
P/S = 6.4488
P/B = 5.564
P/EG = 1.1818
Revenue TTM = 5.85b USD
EBIT TTM = 998.7m USD
EBITDA TTM = 1.33b USD
Long Term Debt = 2.58b USD (from longTermDebt, last fiscal year)
Short Term Debt = 40.1m USD (from shortTermDebt, last quarter)
Debt = 2.85b USD (from shortLongTermDebtTotal, last quarter) + Leases 148.0m
Net Debt = 2.01b USD (calculated: Debt 2.85b - CCE 841.3m)
Enterprise Value = 48.1b USD (46.1b + Debt 2.85b - CCE 841.3m)
Interest Coverage Ratio = 7.77 (Ebit TTM 998.7m / Interest Expense TTM 128.5m)
EV/FCF = 46.53x (Enterprise Value 48.1b / FCF TTM 1.03b)
FCF Yield = 2.15% (FCF TTM 1.03b / Enterprise Value 48.1b)
FCF Margin = 17.67% (FCF TTM 1.03b / Revenue TTM 5.85b)
Net Margin = 14.65% (Net Income TTM 857.0m / Revenue TTM 5.85b)
Gross Margin = 66.95% ((Revenue TTM 5.85b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 68.60% (prev 65.13%)
Tobins Q-Ratio = 3.55 (Enterprise Value 48.1b / Total Assets 13.6b)
Interest Expense / Debt = 4.51% (Interest Expense 128.5m / Debt 2.85b)
Taxrate = 8.10% (75.3m / 930.3m)
NOPAT = 917.8m (EBIT 998.7m * (1 - 8.10%))
Current Ratio = 1.24 (Total Current Assets 2.66b / Total Current Liabilities 2.14b)
Debt / Equity = 0.35 (Debt 2.85b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 1.51 (Net Debt 2.01b / EBITDA 1.33b)
Debt / FCF = 1.94 (Net Debt 2.01b / FCF TTM 1.03b)
Total Stockholder Equity = 7.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.48% (Net Income 857.0m / Total Assets 13.6b)
RoE = 10.74% (Net Income TTM 857.0m / Total Stockholder Equity 7.98b)
RoCE = 9.46% (EBIT 998.7m / Capital Employed (Equity 7.98b + L.T.Debt 2.58b))
RoIC = 8.22% (NOPAT 917.8m / Invested Capital 11.2b)
WACC = 8.74% (E(46.1b)/V(48.9b) * Re(9.02%) + D(2.85b)/V(48.9b) * Rd(4.51%) * (1-Tc(0.08)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.63 | Cagr: -9.51%
[DCF] Terminal Value 76.73% ; FCFF base≈968.3m ; Y1≈1.11b ; Y5≈1.63b
[DCF] Fair Price = 90.11 (EV 23.0b - Net Debt 2.01b = Equity 21.0b / Shares 233.2m; r=8.74% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 98.46 | Revenue CAGR: 10.57% | SUE: 2.64 | # QB: 1
EPS current Quarter (2026-03-31): EPS=1.14 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-06-30): EPS=1.27 | Chg30d=+0.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=3.77 | Chg30d=+0.34% | Revisions=+58% | GrowthEPS=+45.3% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=6.69 | Chg30d=+5.71% | Revisions=+67% | GrowthEPS=+39.7% | GrowthRev=+18.3%
[Analyst] Revisions Ratio: +65% (up=20, down=3)